



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Mortlock et al.  
Serial No: 10/088,856  
Filed: March 21, 2002  
For: Therapeutic Quinazoline Derivatives

Attorney Docket No. Z70598 US  
Art Unit: 1624  
Confirmation No.: 6741  
Examiner: T.N. Truong

Commissioner for Patents  
Alexandria, VA 22313-1450

**Declaration Under 35 U.S.C. §1.132 of**

Sir:

I, Andrew Mortlock of Alderley Park, Macclesfield, Cheshire, UNITED KINGDOM hereby declare as follows:

1. I am a Medicinal Chemist for AstraZeneca and am co-inventor of the above-captioned application, which teaches and claims quinazoline derivatives and uses thereof. I am also a co-inventor of US patent application nos. 10/088814, 10/88852, 10/088854, 10/182454, 10/311916 and 11/070057.

2. The ability of several compounds disclosed in the instant application to inhibit Aurora A kinase was tested using the assay described at page 184, line 13 through page 186, line 32 of the application. The IC<sub>50</sub> values for some of the compounds disclosed therein were as follows:

Compound	IC <sub>50</sub> (μM)
6	0.008
12	0.01
22	0.05
27	0.03
31	0.04
41	0.03
86	0.01
92	0.03
102	0.02
174	0.01
236	0.008
273	0.06
298	0.61

3. These data demonstrate that a wide range of compounds encompassed by the instant claims are able to inhibit Aurora A kinase. In particular, the data show that many substituents at the R<sup>3</sup> and R<sup>5</sup> positions will provide a compound capable of inhibiting Aurora A kinase. Because

of the diversity of substituents on these compounds, I conclude that the compounds assayed in Section 2 of this Declaration are representative of the genus of compounds recited in claim 1, as amended in the Amendment file herewith.

4. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code and that willful false statements may jeopardize the validity of this Application for Patent or any patent issuing thereon.

Andrew Mortlock

Dated: 18 July 2005

Signature: 